Your browser doesn't support javascript.
Induction of trained immunity by influenza vaccination - impact on COVID-19.
Debisarun, Priya A; Gössling, Katharina L; Bulut, Ozlem; Kilic, Gizem; Zoodsma, Martijn; Liu, Zhaoli; Oldenburg, Marina; Rüchel, Nadine; Zhang, Bowen; Xu, Cheng-Jian; Struycken, Patrick; Koeken, Valerie A C M; Domínguez-Andrés, Jorge; Moorlag, Simone J C F M; Taks, Esther; Ostermann, Philipp N; Müller, Lisa; Schaal, Heiner; Adams, Ortwin; Borkhardt, Arndt; Ten Oever, Jaap; van Crevel, Reinout; Li, Yang; Netea, Mihai G.
  • Debisarun PA; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Gössling KL; Department for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
  • Bulut O; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Kilic G; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Zoodsma M; Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Liu Z; TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Oldenburg M; Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Rüchel N; TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Zhang B; Department for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
  • Xu CJ; Department for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
  • Struycken P; Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Koeken VACM; TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Domínguez-Andrés J; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Moorlag SJCFM; Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Taks E; TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Ostermann PN; Department of Occupational Health & Safety, and Environmental Service, Radboud University Medical Center, Nijmegen, Netherlands.
  • Müller L; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Schaal H; Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Adams O; TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Borkhardt A; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Ten Oever J; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • van Crevel R; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Li Y; Institute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
  • Netea MG; Institute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
PLoS Pathog ; 17(10): e1009928, 2021 10.
Article in English | MEDLINE | ID: covidwho-1484868
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Cross Protection / COVID-19 / Immunity, Innate Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Country/Region as subject: Europa Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1009928

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Cross Protection / COVID-19 / Immunity, Innate Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Country/Region as subject: Europa Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: Journal.ppat.1009928